Evidence map›Paper›PMID 40027504›Full record

ArticleFrontiers in public health2025

Global burden and international disparities in NASH-associated liver Cancer: mortality trends (1990-2021) and future projections to 2045.

Qilong Nie, Yongwen Jiang, Mingyang Li, Qiuyan Liang, Xiaoai Mo, Tengyu Qiu, Qunfang Jiang, Kaizhou Huang, Youqing Xie, Ying Chen and 3 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qilong NieThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Yongwen JiangThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Mingyang LiThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Qiuyan LiangThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Xiaoai MoThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Tengyu QiuThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Qunfang JiangThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Kaizhou HuangThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Youqing XieThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Ying ChenThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Xiaojun MaThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Jianhong LiThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Kaiping JiangThe Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: NASH-associated liver cancer (NALC) is a significant contributor to global cancer mortality, closely linked to the increasing prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This study comprehensively examines the global burden of NALC from 1990 to 2021. Methods: This study used data from the Global Burden of Disease (GBD) 2021 database to analyze NALC death and age-standardized death rates (ASDR) globally and regionally from 1990 to 2021. We applied Joinpoint regression analysis to assess temporal trends, calculating the annual percent change (APC) and average annual percent change (AAPC). Decomposition analysis was performed to break down mortality changes into contributions from population aging, growth, and epidemiological changes. A frontier analysis was used to evaluate the relationship between NALC burden and sociodemographic development using the Socio-Demographic Index (SDI). Prediction analysis of NALC deaths and ASDR from 2021 to 2045 were estimated using the Nordpred model. Results: From 1990 to 2021, the global burden of NALC deaths increased significantly, with the ASDR rising from 0.38 per 100,000 in 1990 to 0.48 per 100,000 in 2021. Age-specific data in 2021 revealed that NALC deaths peaked in the 65-69 age group for men and 70-74 age group for women. Decomposition analysis indicated that population growth was the most significant contributor to the global NALC death toll, followed by population aging and epidemiological changes. Frontier analysis showed that countries like Mongolia and Gambia were farthest from the disease burden frontier, while Morocco and Ukraine were closest. Prediction analysis suggest a significant increase in NALC deaths by 2045 compared to 2021, with a larger rise in deaths among women. Conclusion: Through this study, a data-driven approach is provided to reduce the global disease burden of NALC. Essential data support for public health prevention strategies is offered, helping guide the development of targeted government interventions. Trends across global regions, countries, age groups, and genders have been analyzed, providing valuable insights for the formulation of evidence-based policies aimed at mitigating the impact of NALC worldwide.

Indexed as

Global Burden of DiseaseGlobal HealthHealth Status DisparitiesLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseAdultAgedFemaleForecastingHumansMaleMiddle AgedMortalitydecomposition analysisfrontier analysisglobal burden of diseasejoinpoint analysisNASH-associated liver cancerprediction analysis

Identifiers

PMID40027504
PMCPMC11868124

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.